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Abstract: Changes of the tumor necrosis factor-alpha (TNF-) system have been shown to be involved in the develop-
ment of psychiatric disorders and are additionally associated with changes in body weight as well as endocrine and meta-
bolic changes in psychiatric patients.  
TNF- might, for example, contribute to the pathogenesis of depression by an activation of the hypothalamo-pituitary-
adrenocortical (HPA) axis, an activation of neuronal serotonin transporters and the stimulation of the indoleamine 2,3-
dioxygenase which leads to tryptophan depletion. On the other hand, during an acute depressive episode, an elevated HPA 
axis activity may suppress TNF- system activity, while after remission, when HPA axis activity has normalized the sup-
pression of the TNF- system has been shown not to be apparent any more. 
In narcoleptic patients, soluble TNF receptor (sTNF-R) p75 plasma levels have been shown to be elevated, suggesting a 
functional role of the TNF- system in the development of this disorder. 
Additionally, psychotropic drugs influence the TNF- system as well as the secretion and the effect of hormones which 
counteract or interact with the TNF- system such as the intestinal hormone ghrelin. However, only preliminary studies 
with restricted sample sizes exist on these issues, and many open questions remain. 
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INTRODUCTION 
  The brain and the immune system are the two major 
adaptive systems of the body. Both influence and regulate 
each other. Factors stemming from the immune system, such 
as cytokines and chemokines, and factors derived from the 
central nervous system, for example hormones, neurotrans-
mitters and neuropeptides, have an influence on both, the 
brain and the immune system. And there is growing evidence 
that infectious and immune factors may contribute to the 
pathogenesis of neurodevelopmental disorders including 
autism, mental retardation, and schizophrenia [38]. More 
specifically, more and more support for the hypothesis is 
found that the tumor necrosis factor (TNF)- producing 
macrophages play an important role in neurodevelopment 
and in the pathophysiology of various neuropsychiatric con-
ditions [19]. 
  The central nervous system affects the immune system 
mainly through the neuroendocrine outflow via the pituitary, 
and through direct neuronal influences via the sympathetic, 
parasympathetic, peptidergic and sensory innervation of pe-
ripheral tissues. Alternatively, certain cytokines such as in-
terleukin (IL)-1, IL-6 and TNF- released during an immune 
response and other processes the immune system is involved 
in modulate brain activity. These cytokines act on the brain 
via a fast transmission pathway involving primary afferent 
nerves innervating the bodily site of inflammation and a slow  
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transmission pathway involving cytokines originating from 
the choroid plexus and circumventricular organs and diffus-
ing into the brain parenchyma by volume transmission. They 
alter neurotransmitter networks activity and, thus induce 
sleepiness, fatigue, loss of appetite and decreased libido. 
These symptoms have been described as “sickness behav-
iour” and are related to the behavioral changes of depression 
[15].  
  Among the different ways of bidirectional influence be-
tween the immune system and the central nervous system, 
one cytokine has recently attracted a lot of scientific interest: 
TNF-. This review focuses on the TNF- system, although 
other cytokines do also contribute to the interaction between 
the brain and the immune system and, in part, amplify the 
effects of TNF-.
THE TNF- SYSTEM 
 TNF- is a 185 amino acid glycoprotein hormone, which 
was isolated in 1975 by Carswell et al. as a soluble factor 
released by host cells that caused necrosis of a transplanted 
tumor [9]. Once TNF- was cloned in 1985, the involvement 
of this cytokine in infectious disease pathology was pursued 
by a number of groups. By the late 1980s excess TNF- pro-
duction was proposed to be central to acute systemic viral 
diseases. This family of cytokines is now at the centre of 
investigations to understand the mechanisms of acute sys-
temic viral diseases, including influenza and the hemorrhagic 
viral diseases. With its implication as the master regulator of 
other inflammatory cytokines in the synovial membrane, 
TNF- has also become the major cytokine in the pathogene-
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proven to be a potent treatment for rheumatoid arthritis and 
Crohn's disease [12]. 
 TNF- is a multifunctional signaling molecule with im-
portant functions in inflammation and apoptosis [21]. It 
plays a significant role in the defense against viral, bacterial 
and parasitic infections as well as in autoimmune disorders 
and energy homeostasis [18]. TNF- is released by mono-
cytes / macrophages and other white blood cells, the endo-
thelium, the adipose tissue and several other tissues. It is 
considered to be one of the most important factors of in-
flammation and cachexia [67]. In conclusion, it has a wide 
range of functions within the body, including a role in im-
mune response, inflammation, apoptosis, and energy homeo-
stasis. It is involved in several regulatory processes within 
the body [26]. 
  The action of TNF- at the cellular level is mediated by 
two cell surface receptors, TNF-R p55 and TNF-R p75. 
TNF-R p55 is expressed in most tissues, whereas expression 
of TNF-R p75 is highly regulated and typically found in cells 
of the immune system. Accordingly, in the vast majority of 
cells, TNF-R p55 appears to be the key mediator of TNF-
signaling, whereas in the lymphoid system, TNF-R p75 
seems to play a major role [101]. When bound to TNF-, the 
TNF-Rs transduce growth regulatory signals into the cell. 
Via these receptors, TNF- is mitogenic in normal cells; 
however, TNF- initiates apoptosis in transformed cells 
causing DNA fragmentation and cytolysis. Whether TNF-
induces cell differentiation or apoptosis via the TNF-Rs de-
pends on the signaling pathway activated within the cell. The 
TNF--induced survival pathway seems to be mediated by 
the transcription factor nuclear factor-kappaB (NF-KB), as 
recent studies have demonstrated that cells in which the NF-
KB signaling pathway is blocked are more likely to undergo 
apoptosis in response to TNF- [72]. 
  In cases in which TNF- induces apoptosis, it has been 
shown that one of the crucial intracellular signaling event is 
the sequential activation of caspases, a family of cysteine 
proteases [1]. 
  The membrane-bound TNF-Rs can be proteolytically 
cleaved from the cell membrane by the proteolytic action of 
a disintegrin metalloproteinase called TNF- converting en-
zyme (TACE) [77]. Therefore, soluble TNF-Rs (sTNF-Rs) 
are soluble variants of the extracellular domains of their 
membrane-bound form. Although soluble forms of cytokine 
receptors such as sTNF-R p75 are thought to control cyto-
kine activity in vivo by inhibiting the ability of cytokines to 
bind to their membrane receptors and thus inhibiting a bio-
logical response, elevated plasma levels of sTNF-R p75 indi-
cate an inflammatory process in several diseases, for exam-
ple rheumatoid arthritis [20]. Fig. (1) shows a simplified 
scheme of the TNF- system and the components described 
above. 
METABOLIC AND NEUROENDOCRINE ASPECTS 
OF THE TNF- SYSTEM 
  Obesity is associated with a chronic low-grade inflamma-
tion and an increased abundance of macrophages in the white 
adipose tissue. The macrophages seem to lead to a chronic 
activation of the innate immune system. This low-grade in-
flammation results can subsequently lead to insulin resis-
tance, impaired glucose tolerance and even diabetes [5]. 
  The energy balance and weight regulation, the control of 
appetite and feeding are based on a complex network of 
hormones, cytokines, neurotransmitters and neuromodula-
tors. One of them is the 28-amino acid peptide hormone 
ghrelin which regulates feeding behaviour through modula-
tion of expression of the orexigenic peptides, neuropeptide Y 
and agouti-related protein in the hypothalamus [60, 98]. 
Ghrelin is secreted in the gastrointestinal tract and correlates 
inversely with the body mass index and fat percentage [99]. 
It could be shown that ghrelin administration increases food 
intake and body weight, while weight loss increases ghrelin 
levels. Ghrelin is an important factor of energy balance, 
weight regulation and the control of appetite and feeding, 
and its dysregulation is assumed to play an important role 
regarding obesity [14, 47, 60, 98, 108, 109]. Therefore, TNF-
 and ghrelin seem to be opponents regarding the hypotha-
lamic regulation of eating behavior as TNF- has an 
anorexigenic effect and ghrelin exhibits an orexigenic effect 
on an hypothalamic level. 
  Additionally, ghrelin, and its target receptors, the growth 
hormone secretagogue receptors (GHS-Rs), have been local-
ized to neutrophils, lymphocytes, and macrophages, which 
suggests that ghrelin may be involved in the process of im-
mune modulation. And indeed, ghrelin has potent anti-
inflammatory properties through modulation of secretion of 
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bothpro-inflammatory and anti-inflammatory cytokines from 
macrophages [104]. Overall, ghrelin exhibits anti-inflam-
matory effects as well as immunoregulatory effects that may 
be mediated through the GHS-R-1a receptor [116] and 
through activation of the vagus nerve [110]. It down-regu-
lates pro-inflammatory cytokines and inhibites NF-kappaB 
activation. E.g. ghrelin could be shown to improve survival 
rates of rats with sepsis-induced acute lung injury [111], 
might ameliorate neuropathic pain by diminishing the pro-
inflammatory cytokines and regulating pain system [22], and 
therefore may be a possible anti-inflammatory drug in the 
future. To conclude, on the level of immune cells, ghrelin 
also seems to counteract the effect of pro-inflammatory cy-
tokines. 
  In obesity, the white adipose tissue is characterized by an 
increased production and secretion of a wide range of in-
flammatory molecules including TNF-, which may have 
local effects on white adipose tissue physiology but also sys-
temic effects on other organs. Interestingly, weight loss is 
associated with a reduction in the macrophage infiltration of 
white adipose tissue and an improvement of the inflamma-
tory profile of gene expression. Several factors derived not 
only from adipocytes but also from infiltrated macrophages 
probably contribute to the pathogenesis of insulin resistance. 
Most of them are overproduced during obesity, including 
leptin, TNF-, IL-6 and resistin [5].  
  Macrophages exist in separate types of differentiation, 
but the nature of adipose tissue macrophages is largely un-
known. However, in a study of Zeyda et al. [114] basal and 
induced secretion of pro-inflammatory mediators such as 
TNF- was even higher in adipose tissue macrophages than 
in other pro-inflammatory macrophages.  
  Therefore, it could be shown by several investigations 
that body fat mass influences TNF- plasma levels [64, 66]. 
However, much less is known about plasma levels of its 
soluble receptors sTNF-R p55 and sTNF-R p75. In a study 
with more than 500 randomly chosen adults, plasma levels of 
TNF- and also sTNF-Rs correlated significantly with the 
BMI [31]. 
 Asincreased pro-inflammatory cytokine levels are known 
to be associated with cardiovascular disease [25, 41, 81], 
silent brain infarctions [39], and a worse prognosis after 
stroke [102], Park et al. concluded that the positive associa-
tions of obesity and visceral adiposity with elevated cytokine 
levels suggest the importance of reducing obesity and vis-
ceral adiposity to prevent elevations in cytokine levels and 
associated diseases [65]. 
  Cytokines such as TNF- link the non-specific immune 
system to the hypothalamo-pituitary-adrenocortical (HPA) 
axis: inflammatory cytokines — such as TNF- and its solu-
ble receptors p55 and p75 — released during infection and 
inflammation activate the HPA system at the hypothalamic, 
pituitary, and adrenal level resulting in the release of cortisol 
as the most important negative feedback signal to prevent an 
overshoot of the ongoing host defense [42, 89, 96]; glucocor-
ticoids, in turn, suppress the production of pro-inflammatory 
cytokines. Moreover, a chronically activated HPA axis as 
occurring during chronic stress results in defective immune 
system responses to an inflammatory challenge [3, 6, 80, 84]. 
It could be shown in tumor bearing patients that exogenous 
TNF- administration leads to a corticotropin-releasing hor-
mone (CRH), adrenocorticotropic hormone (ACTH) and 
cortisol release [55], while glucocorticoid administration in 
healthy subjects suppresses TNF- production, and the cir-
cadian rhythm of endogenous glucocorticoids appears to be 
inversely correlated with the pro-inflammatory cytokine pro-
duction [69]. Fig. (2) is ment to show the interactions be-
tween the TNF- system and the HPA axis and its negative 
feedback mechanism. 
  Additionally, cytokines such as TNF- exert other effects 
on the hypothalamic level. The pro-inflammatory cytokines 
IL-1, IL-6 and TNF- have been most investigated for their 
pyrogenic action. The experimental evidence demonstrates 
the role of these secreted proteins in modulating the fever 
response. An association between cytokine levels in serum 
and cerebrospinal fluid and fever, the finding of the presence 
of cytokine receptors on various cell types in the brain and 
demonstration of the effects of pharmacological application 
of cytokines and of their neutralizing antibodies on the fever 
response and fever studies on cytokine- and cytokine recep-
tor-transgenic models underline the strong influence of cyto-
kines on hypothalamic thermoregulation [13]. 
  Cytokine-induced loss of appetite is consistently ob-
served during cytokine immunotherapy in humans. Investi-
gators have also shown that cytokines induce anorexia when 
administered peripherally or into the brain. Anorexigenic 
cytokines by central action include IL-1, IL-6, leptin, IL-8, 
TNF-, and interferon (IFN)-. Cellular approaches indicate 
that modulation of hypothalamic activity is involved in cyto-
kine-induced anorexia. Cytokine action involves the modula-
tion of specific neurons that are proposed to participate in the 
control of feeding, i.e. glucose-sensitive neurons in the lat-
eral hypothalamic area and hypothalamic ventromedial nu-
cleus [71]. Appetite loss and fever lead to lipolysis, lipid 
mobilization and a reduction of the fatty tissue.  
Fig. (2). Simplified scheme of interactions between the TNF- system and the HPA axis. Exogenous TNF- administration in tumor 
bearing patients leads to a release of corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH) and cortisol, while glu-
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  One condition already mentioned in which TNF- is pro-
duced and secreted into the blood is obesity. Nowadays the 
concurrence of rich food and physical idleness is an increas-
ing problem and established risk factor for various diseases 
in affluent countries. Different combinations of obesity, dia-
betes, hypertriglyceridemia and insulin resistance cause he-
patic steatosis, which can trigger necroinflammation and 
fibrosis. Patients with steatohepatitis exhibit ultrastructural 
mitochondrial lesions. Mitochondria play a major role in fat 
oxidation and energy production but also leak reactive oxy-
gen species (ROS) and are the main cellular source of ROS. 
In patients with steatosis, mitochondrial ROS may oxidize 
hepatic fat deposits. Lipid peroxidation products impair the 
flow of electrons along the respiratory chain, which may 
cause overreduction of respiratory chain components, further 
increasing mitochondrial ROS formation and lipid peroxida-
tion. Lipid peroxidation, in turn, causes further cytokine in-
duction [68]. 
THE TNF- SYSTEM AND DEPRESSION 
  Several psychiatric disorders are reported to be associ-
ated with alterations of the cytokine system. In this article, 
hypotheses regarding associations of major depression, an 
affective disorder, and narcolepsy, a sleep disorder, with the 
TNF- system are demonstrated. Additionally, one should 
keep in mind that the TNF- system is as well involved in 
the development of other brain disorders such as multiple 
sclerosis, Parkinson’s disease and Alzheimer’s disease [26]. 
  Modern neurobiological methods have revealed patho-
physiological mechanism associated with depression. The 
monoamine hypothesis, which was advocated in the 1950s, 
emphasizes that the deficiency of monoamine neurotransmit-
ters, for example serotonin, brings about depressive symp-
toms. This theory played an important role in promoting the 
development of new antidepressants and it is underlined by 
genetic findings of polymorphisms of serotonin transporter 
gene associated with depression. Neuroendocrine studies 
have revealed the HPA axis dysfunctions in depressive pa-
tients and increased activity of HPA axis are considered as 
state marker of depression [93]. Several findings indicate an 
influence of the cytokine system, of which TNF- is a part, 
on serotonin metabolism as well as on the HPA axis. 
  Alterations in plasma cytokine levels have repeatedly 
been found in patients suffering from affective disorders [23, 
52], and evidence suggests that cytokines may be involved in 
the development of depression [76]. It has been postulated 
that the activation of the cytokine system might play a causa-
tive role in the depression-related activation of the HPA sys-
tem [51, 63], and experimental studies applying immune 
stimulation in humans [78, 79] as well as in rodents [50, 
112] showed that immune stimulation induces depression-
like signs and symptoms supporting the view that inflamma-
tory cytokines are causally involved in behavioral alterations 
of patients with depressive disorders. 
  In contrast, Schuld et al. reported data suggesting that 
chronic HPA system overactivity in depressed patients sup-
presses the production of inflammatory cytokines [86]. In 
another study on the mutual influence of the HPA system 
and the TNF- system in depressed patients without inflam-
matory diseases, TNF- levels were inversely associated 
with the ACTH response to the combined dex/CRH test and 
it was concluded that elevated HPA axis activity in acute 
depression suppresses TNF- system activity [29]. There-
fore, the activated HPA axis in depressed patients seems to 
suppress the activity of the cytokine system. 
  As pro-inflammatory cytokines and serotonergic homeo-
stasis have both been implicated in the pathophysiology of 
major psychiatric disorders, Zhu et al. hypothesized that cy-
tokines might also activate neuronal serotonin transporters. 
This idea would underline the theory of a serotonin defi-
ciency during depression and the pharmacodynamic mecha-
nism of selective serotonin reuptake inhibitors (SSRI) in the 
treatment of depression, because SSRIs lead to recovery 
from depression via deactivation of serotonin transporters. 
Indeed, Zhu et al. found TNF- stimulated serotonin uptake 
in both a rat embryonic raphe cell line and in mouse mid-
brain and striatal synaptosomes. These results provided evi-
dence that pro-inflammatory cytokines can acutely regulate 
neuronal serotonin transporter activity. A mitogen-activated 
protein kinase may be in involved in this mechanism [117]. 
  Pro-inflammatory cytokines such as IL-1 and TNF-
affect the tryptophan metabolism directly or indirectly by 
stimulating the enzyme indoleamine 2,3-dioxygenase which 
leads to a peripheral depletion of tryptophan [106]. And the 
aromatic amino acid tryptophan functions as precursors for 
the monoamine neurotransmitter serotonin in the brain. 
  Therefore, we can hypothesize three mechanisms how 
cytokines may lead to depression or depressive symptoms: 
the activation of the HPA axis, the activation of neuronal 
serotonin transporters and the stimulation of the indoleamine 
2,3-dioxygenase which leads to tryptophan depletion. 
THE TNF- SYSTEM AND NARCOLEPSY 
  Narcolepsy is a disabling sleep disorder characterized by 
excessive daytime sleepiness, cataplexy, hypnagogic halluci-
nation, and sleep paralysis [62]. Since the discovery of the 
extremely close association of narcolepsy and the human 
leukocyte antigen HLA-DR2 [48, 56] it has been suggested 
that the immune system might play a pathogenic role, be-
cause it is known that HLA haplotypes are linked to a num-
ber of autoimmune diseases [57]. In human narcoleptics, a 
dramatic reduction in the number of hypocretin neurons 
could be observed [16]. Because of the association of narco-
lepsy with HLA-DR2 it was hypothesized that the loss of 
these neurons might be caused by an autoimmune process 
[94]. 
  Furthermore, a small number of studies suggest that cer-
tain cytokine-producing genes may predispose to narcolepsy. 
Hohjoh  et al. [37] conducted an association study of the 
TNF-R p75 polymorphisms with human narcolepsy and 
found that the 196 R allele was significantly more frequent 
in narcoleptic patients suggesting that this allele is associated 
with the susceptibility to narcolepsy.  
  In a sample of 30 narcoleptic patients in comparison to 
120 gender- and age-matched and 101 gender-, BMI- and 
age-matched randomly selected normal controls, sTNF-R 
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tients, even if compared to gender-, BMI- and age-matched 
counterparts. It was concluded that narcoleptic patients show 
increased plasma levels of sTNF-R p75 suggesting a func-
tional alteration of the TNF- cytokine system and further 
corroborating a possible pathogenic role of the immune sys-
tem in this sleep disorder [28]. One possible hypothesis 
would be that the activation of the TNF- system and a 
sTNF-R p75-mediated activation of cells of the immune sys-
tem would lead to an autoimmune destruction of hypocretin 
neurons, which seems to be strongly associated with the de-
velopment of narcolepsy. This destruction may involve T-
helper cells (TH), cytotoxic T cells and lymphocytes. 
  In conclusion, TNF- may lead to psychiatric disorders 
via an activation of a neuroendocrine system such as the 
HPA axis, the activation of neurotransmitter transporters 
such as the serotonin transporter, the influence on the me-
tabolism of neurotransmitters and the autoimmune destruc-
tion of neurons. 
THE TNF- SYSTEM AND OTHER DISEASES OF 
THE BRAIN 
  In addition to its immunological and metabolic proper-
ties, TNF- promotes nerve cell growth and differentiation, 
and is cytotoxic to oligodendrocytes [54]. The gene that en-
codes TNF- is mapped to chromosome 6p21.3–p21.1 [91], 
a region linked in several studies to Schizophrenia [2, 49, 87, 
103]. 
 Thus,  TNF- might be involved in the process of neuro-
development and neurodegeneration, which could link to the 
pathogenesis of Schizophrenia by subtle alterations in neu-
ronal number and density [105]. A functional single nucleo-
tide polymorphism within the promoter region of the TNF-
gene, has been related to the pathogenesis of several dis-
eases, including Schizophrenia [107]. TNF- has pleiotro-
phic effects on neurons, particularly in glutamate excitotox-
icity by inhibiting glial glutamate transporters on astrocytes 
directly and indirectly [70]. The G-308A polymorphism of 
the TNF- gene might be involved in antipsychotic response 
[112]. 
 The  TNF- system has also been shown to be involved in 
the development of other brain diseases such as multiple 
sclerosis (MS). In MS patients, the inflammatory demyelini-
sation seems to be mediated by the presence of TNF- lead-
ing to myelin and oligodendrocyte destruction [46]. One 
source of TNF- production may be the dendritic cells [43]. 
TNF- induces neurotoxicity via glutamate release from 
hemichannels of activated microglia in an autocrine manner. 
This mechanism may contribute to neuronal damage in neu-
rodegenerative diseases including Alzheimer’s disease, Park-
inson’s disease, amyotrophic lateral sclerosis and multiple 
sclerosis [92]. 
CHANGES OF THE TNF- SYSTEM DURING PSY-
CHOPHARMACOLOGICAL TREATMENT 
  Weight gain in patients on psychotropic medication is a 
frequent side effect of prominent clinical relevance, occur-
ring under antipsychotics and antidepressants. 
  In recent years, studies have been conducted on neuroen-
docrine and neuroimmunological mechanisms involved in 
appetite and weight regulation. Regarding these mechanisms, 
the TNF- system might play a particular role. All drugs 
investigated so far that induce weight gain - clozapine, olan-
zapine, amitriptyline and mirtazapine – also clearly activate 
the TNF- system [36, 44, 75, 85]. This activation results in 
increased plasma levels of soluble sTNF-Rs and TNF- lev-
els. 
  Recently, the influence of the mood stabilizer carba-
mazepine on leptin and the TNF- system has been investi-
gated, too. Lithium, for example, demonstrated significant 
immunoregulatory effects by increasing the in vitro produc-
tion of TNF- in healthy volunteers [52], and the TNF- and 
sTNF-R p75 levels have already been shown to be signifi-
cantly increased cross-sectionally in patients treated with 
lithium [23]. 
  A longitudinal study on the influence of carbamazepine 
and lithium on TNF- plasma levels has been conducted. An 
increase in the body mass index and in TNF- and its soluble 
receptor levels over the 4 weeks of treatment was found in 
both treatment groups [33]. 
  Is not clear, however, whether the activation of the TNF-
 system by psychotropic drugs is the cause or a conse-
quence of weight gain during psychopharmacological treat-
ment. As mentioned above, recent data indicate that white 
adipose tissue is infiltrated by macrophages, which may be a 
major source of locally produced pro-inflammatory cytoki-
nes [5], in case of increasing body weight. 
  Activation of the TNF- system seems to be specific for 
psychotropic drugs that induce weight gain, since drugs 
which did not affect or even decreased weight (haloperidol, 
paroxetine, venlafaxine) did not influence the TNF- system 
at all [33, 36, 74, 75, 85]. Moreover, the antidepressant 
bupropion, which reduces body weight, lowers the produc-
tion of TNF- in mice [7]. An overview of the TNF- and 
TNF-R production-inducing properties of various psycho-
pharmacological agents is shown in Table 1.
  Abnormal liver function tests are frequently encountered 
in patients receiving psychopharmacological treatment [17]. 
All kinds of psychotropic drugs can elevate liver enzyme 
levels and have the potential to induce liver damage [88]. In 
a study on liver enzyme levels during psychopharmacologi-
cal treatment in patients who received a stable psychophar-
macological treatment, an increase in aspartate-aminotrans-
ferase (ASAT) and alanine-amino transferase (ALAT) 
plasma levels was found. This increase in ALAT and ASAT 
levels was most pronounced at week three. Analyzing the 
changes from baseline to week three, among several other 
parameters, changes in TNF- levels were significantly asso-
ciated with changes in ALAT [32]. 
  This finding suggests that the effects of psychotropic 
drugs on the TNF- cytokine system – independent of 
weight gain – might contribute to early changes in liver en-
zyme levels. This idea is in line with present evidence al-
ready mentioned earlier that cytokines might be involved in 
liver damage [10, 40, 97]. This might be particularly true for 
substances such as clozapine that have independent effects 
on weight regulation and the TNF- system [4, 35]. But be-
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psychopharmacological therapy seems to be the best predic-
tor for liver enzyme elevation during a treatment period of 
several weeks [32]. 
  In a small study with 24 depressed patients we sought to 
determine whether changes in TNF- and its receptor plasma 
levels early during antidepressant therapy are predictors of 
psychopharmacologically induced weight change. Changes 
of weight during the first week of treatment, but no parame-
ter of the TNF- system strongly predicted weight change 
until endpoint of the study. Therefore, changes regarding the 
TNF- system do not seem to be a clinically useful predictor 
of future weight development during psychopharmacological 
therapy [34], but to know exactly more research needs to be 
done in this area. 
  As mentioned above, the effects of the TNF- system 
may be modulated or even counteracted by the intestinal 
hormone ghrelin. Ghrelin recently became a target of re-
search regarding investigations on weight gain during psy-
chopharmacological treatment.  
  Regarding antipsychotic treatment for example, it was 
reported that olanzapine would increase plasma ghrelin lev-
els in patients with schizophrenia [59] and that acute admini-
stration of clozapin increases circulating plasma ghrelin lev-
els in rats [58]. Data of other studies, however, did support 
the hypothesis of a causal involvement of ghrelin in antipsy-
chotic-induced weight gain [30, 82, 95]. However, changes 
in weight during treatment with antipsychotics may be the 
cause for changes regarding ghrelin secretion. These interre-
lations may be elucidated by future research. 
  Regarding antidepressant treatment, the role of ghrelin 
seems to be much more complex and the various study re-
sults are not sufficient to lead to a common hypothesis for 
the role of ghrelin in antidepressant treatment. For example, 
tryptophan – the precursor molecule of serotonin – enhances 
ghrelin expression and secretion [115], antidepressant ther-
apy with an SSRI may attenuate hypothalamic effects of 
ghrelin [8], and antidepressant therapy with mirtazapine 
seems to decrease ghrelin levels [83]. To our knowledge, 
studies investigating TNF- as well as ghrelin levels during 
antidepressant treatment are not available. 
PERSPECTIVES 
  It is pharmacologically possible to give a TNF- blocker 
to a patient. One of these new drugs is etanercept. It can, for 
example, be used for the treatment against the autoimmune 
disease psoriasis. Psoriasis has substantial psychological and 
emotional effects. Therefore, Tyring et al. assessed the effect 
of etanercept on fatigue and symptoms of depression associ-
ated with the condition. 618 patients with moderate to severe 
psoriasis received double-blind treatment with placebo or 50 
mg twice-weekly etanercept. The primary efficacy endpoint 
was a 75% or greater improvement from baseline in psoriasis 
area and severity index score at week 12. Secondary end-
points included the functional assessment of chronic illness 
therapy fatigue scale, the Hamilton Depression Rating Scale 
(HAMD), the Beck depression inventory (BDI), and adverse 
events. In this study, greater proportions of patients receiving 
etanercept had at least a 50% improvement in the HAMD or 
BDI at the endpoint of the study; patients treated with etan-
ercept also had significant and clinically meaningful im-
provements in fatigue. The improvements in symptoms of 
depression were less correlated with objective measures of 
skin clearance or joint pain. The authors concluded that etan-
ercept treatment might relieve fatigue and symptoms of de-
pression associated with this chronic disease [100]. This ob-
servation together with the theoretical background reported 
in this article leads to the hypothesis, that TNF- blocker 
might be useful novel antidepressant agents. 
  One should also consider, whether cytokines could be 
involved in the development of morphological changes of 
hippocampus and down regulation of neurotrophin observed 
in depressive patients. But no investigations are available 
regarding these associations.  
Table 1.  Effects of Different Psychopharmacological Agents on Body Weight and Plasma Levels of TNF- and its Soluble Recep-
tors According to [7, 33, 44, 73, 91, 118] 
 Body  weight  TNF-  sTNF-R p55  sTNF-R p75 
Clozapine     
Olanzapine     
Amitriptyline     
Mirtazapine     
Lithium     
Carbamazepine     
Haloperidol   
Paroxetine   
Venlafaxine   
Bupropion     n. i.  n. i. 
Abreviations: increase (), decrease (), no systematical change (), not investigated (n. i.), tumor necrosis factor-alpha (TNF-), soluble TNF receptor (sTNF-R). The TNF- System  Current Neuropharmacology, 2008, Vol. 6, No. 3    199
  Recent genetic research points at the importance of 
caspase genes for the predisposition to major depression 
[24], and caspases are one intracellular signaling way of 
TNF- signaling. Moreover, genetic findings point at the 
importance of the NF-kappaB-inducing kinase (NIK) in the 
pathogenesis of bipolar affective disorders. For the role of 
NIK in TNF- signaling see Fig. (1) [61]. These and further 
genetic findings may elucidate the way how TNF- is patho-
physiologically involved in the development of affective 
disorders. 
LIMITATIONS 
  This review focuses on plasma levels of TNF- and its 
soluble receptors. Other inflammatory and anti-inflammatory 
cytokines act together with TNF- and should therefore at 
least be mentioned. We chose the TNF- system as an issue 
of this review, because significant findings regarding its in-
volvement in brain disorders - such as depression, narco-
lepsy, multiple sclerosis, Alzheimer’s and Parkinson’s dis-
ease - and psychopharmacology have been reported in sev-
eral study reports [26]. In the majority of studies regarding 
the TNF- system and psychiatric disorders or psychophar-
macological treatment, it would have also been useful to 
determine the concentration of anti-inflammatory cytokines 
such as IL-10 or IL-4 to assess the degree of imbalance be-
tween the inflammatory and anti-inflammatory arms of the 
immune system, but this issue has not been addressed sys-
tematically during psychoimmunological research. 
  As the majority of the mentioned studies are cross-
sectional, caution is recommended regarding conclusions 
about the causality. The conclusion that elevated cytokine 
levels may contribute to the pathogenesis of depression is 
derived from the literature combining the conclusions of 
several studies, but can not be substantiated from longitudi-
nal studies. Therefore, it would be necessary to strengthen 
experimental and longitudinal clinical research in animals 
and humans investigating the effect of cytokines on mood 
over a certain period of time.  
  One could argue that the cited studies reported mainly 
plasma levels of TNF- and its soluble receptors. This is an 
important demur. On the other hand, Sorge [90] reported an 
increase of TNF- and sTNF-R levels during treatment with 
clozapine, as it was expected from the observations of in-
creasing plasma levels of TNF- and sTNF-R levels within 
the blood. Additionally, Churchill et al. [11] reported that 
systemic application of TNF- increases TNF- mRNA lev-
els in the hypothalamus, hippocampus and the somatosen-
sory cortex. Therefore, one can expect that plasma levels of 
TNF- correlate with the TNF- level within the brain. 
  To conclude, only preliminary studies with restricted 
sample sizes exist on most of the mentioned issues, and 
many open questions remain. 
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